Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Tauopathies

ClinicalTrials.gov lists 4,023 trials for Tauopathies or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 62.

MeSH D024801 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 547 Phase 1/2 Phase 1/2 98 Phase 2 Phase 2 583 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 291 Phase 4 Phase 4 138 Not applicable Not applicable 1,427 Observational Observational 870 Phase 1 Phase 1 547 Phase 1/2 Phase 1/2 98 Phase 2 Phase 2 583 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 291 Phase 4 Phase 4 138 Not applicable Not applicable 1,427 Observational Observational 870

Trials per phase (log scale)

1 more section with rows

71 of the 4,023 trials are tagged with Tauopathies itself; the rest are tagged with a narrower condition beneath it.

Get the Tauopathies report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Tauopathies trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 273

1994: 1 trials (Observational 1) 1995: 6 trials (Observational 2, Phase 3 4) 1996: 3 trials (Not applicable 1, Phase 4 1, Phase 2 1) 1997: 3 trials (Observational 1, Phase 3 2) 1998: 4 trials (Phase 4 1, Phase 3 2, Phase 2 1) 1999: 13 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 5) 2000: 22 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 3 9, Phase 2 3, Phase 1 1) 2001: 21 trials (Observational 3, Not applicable 4, Phase 4 1, Phase 3 9, Phase 2/3 2, Phase 2 1, Phase 1 1) 2002: 21 trials (Observational 6, Not applicable 2, Phase 4 3, Phase 3 6, Phase 2 4) 2003: 48 trials (Observational 13, Not applicable 3, Phase 4 8, Phase 3 14, Phase 2/3 1, Phase 2 7, Phase 1 2) 2004: 51 trials (Observational 10, Not applicable 6, Phase 4 5, Phase 3 5, Phase 2/3 3, Phase 2 14, Phase 1/2 4, Phase 1 4) 2005: 55 trials (Observational 11, Not applicable 9, Phase 4 7, Phase 3 7, Phase 2 16, Phase 1 5) 2006: 70 trials (Observational 9, Not applicable 7, Phase 4 10, Phase 3 4, Phase 2/3 2, Phase 2 24, Phase 1/2 1, Phase 1 13) 2007: 110 trials (Observational 17, Not applicable 14, Phase 4 9, Phase 3 15, Phase 2/3 3, Phase 2 18, Phase 1/2 1, Phase 1 33) 2008: 118 trials (Observational 16, Not applicable 12, Phase 4 11, Phase 3 14, Phase 2/3 1, Phase 2 27, Phase 1/2 2, Phase 1 35) 2009: 146 trials (Observational 30, Not applicable 18, Phase 4 4, Phase 3 15, Phase 2/3 2, Phase 2 35, Phase 1/2 3, Phase 1 39) 2010: 121 trials (Observational 17, Not applicable 34, Phase 4 5, Phase 3 14, Phase 2/3 3, Phase 2 15, Phase 1/2 4, Phase 1 29) 2011: 104 trials (Observational 27, Not applicable 20, Phase 4 5, Phase 3 5, Phase 2 30, Phase 1 17) 2012: 137 trials (Observational 30, Not applicable 35, Phase 4 8, Phase 3 8, Phase 2/3 5, Phase 2 28, Phase 1/2 4, Phase 1 19) 2013: 120 trials (Observational 25, Not applicable 41, Phase 4 4, Phase 3 12, Phase 2/3 3, Phase 2 10, Phase 1/2 2, Phase 1 23) 2014: 131 trials (Observational 29, Not applicable 40, Phase 4 6, Phase 3 11, Phase 2/3 2, Phase 2 16, Phase 1/2 3, Phase 1 24) 2015: 148 trials (Observational 26, Not applicable 46, Phase 4 4, Phase 3 8, Phase 2/3 5, Phase 2 22, Phase 1/2 4, Phase 1 33) 2016: 189 trials (Observational 48, Not applicable 70, Phase 4 4, Phase 3 12, Phase 2/3 2, Phase 2 22, Phase 1/2 3, Phase 1 28) 2017: 162 trials (Observational 33, Not applicable 62, Phase 4 3, Phase 3 8, Phase 2/3 4, Phase 2 25, Phase 1/2 8, Phase 1 19) 2018: 197 trials (Observational 40, Not applicable 80, Phase 4 3, Phase 3 11, Phase 2/3 3, Phase 2 33, Phase 1/2 3, Phase 1 24) 2019: 235 trials (Observational 52, Not applicable 113, Phase 4 5, Phase 3 6, Phase 2/3 2, Phase 2 24, Phase 1/2 6, Phase 1 27) 2020: 197 trials (Observational 40, Not applicable 87, Phase 4 2, Phase 3 10, Phase 2/3 4, Phase 2 21, Phase 1/2 10, Phase 1 23) 2021: 261 trials (Observational 70, Not applicable 106, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 30, Phase 1/2 9, Phase 1 29) 2022: 273 trials (Observational 74, Not applicable 123, Phase 4 5, Phase 3 13, Phase 2/3 1, Phase 2 28, Phase 1/2 7, Phase 1 22) 2023: 247 trials (Observational 64, Not applicable 116, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 28, Phase 1/2 8, Phase 1 22) 2024: 267 trials (Observational 61, Not applicable 129, Phase 4 4, Phase 3 8, Phase 2/3 4, Phase 2 32, Phase 1/2 4, Phase 1 25) 2025: 268 trials (Observational 55, Not applicable 137, Phase 4 1, Phase 3 17, Phase 2/3 1, Phase 2 31, Phase 1/2 3, Phase 1 23)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 231
2025 268
2024 267
2023 247
2022 273
2021 261
2020 197
2019 235
2018 197
2017 162

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 250 trials starting in 2026 and about 260 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 410 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 2,394 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Tauopathies trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 547
Phase 1/2 98
Phase 2 583
Phase 2/3 63
Phase 3 291
Phase 4 138
Not applicable 1,427
Observational 870
Expanded access 6

How many Tauopathies trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 181
Recruiting 580
Enrolling by invitation 67
Active, not recruiting 160
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Tauopathies trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 62
Eli Lilly and Company 57
Avid Radiopharmaceuticals 43
National Institute on Aging (NIA) 42
Wyeth is now a wholly owned subsidiary of Pfizer 32

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Tauopathies? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Flortaucipir F18 26
Lecanemab 17
AAB-001 16
Donanemab 15
Florbetaben F18 14

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Donepezil HCI (drug) 114
memantine ER 40
F-18 florbetapir 39
Galantamine ER 33
Rivastigmine 5 cm^2 20

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Tauopathies trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Positive for PDM and had PCC visit 1,775 1
Hospitalizations 1,067 3
Fall 953 134
Positive for PDM and had ER visit 810 1
Pneumonia 736 132

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Tauopathies? (49)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. Science translational medicine 2025 Yes
Neuronal and glial vulnerability of the suprachiasmatic nucleus in tauopathies: evidence from human studies and animal models. Molecular neurodegeneration 2024 Yes
A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau. The journal of prevention of Alzheimer's disease 2024 Yes
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial. The journal of prevention of Alzheimer's disease 2022 Yes
Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults. Neurobiology of aging 2021 Yes

Showing 5 of 49 publications.

Start your 14-day trial Email me all 49 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages